85.83亿美元,这是默沙东近期公布的旗下HPV疫苗(四价以及九价HPV疫苗)在2024年的销售额。 在2024年全球疫苗销售榜单中,默沙东的HPV疫苗取代辉瑞新冠疫苗,位列第一,但销售额称霸的同时,增长疲态已显现。2024年,默沙东的HPV疫苗销售额以3%的同比下滑,告别了过去多年高歌猛进的态势,这跟中国市场销售下滑密不可分。 从2025年起,在中国市场,默沙东的四价HPV疫苗正在向男性市场...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.